此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

GH56 Monotherapy for Second-line Treatment of MTAP-Deleted ESCC

2026年11月10日 更新者:Suzhou Genhouse Bio Co., Ltd.

A Multicenter, Open-Label Study to Evaluate Efficacy and Safety of GH56 Monotherapy for Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With MTAP Deficiency

This is a Phase 2/3, open-label, multicenter study to evaluate the efficacy and safety of GH56 as a single agent in participants with advanced Esophageal Squamous Cell Carcinoma(ESCC) with methylthioadenosine phosphorylase (MTAP) deficiency in the second-line or later setting. In this seamlessly designed Phase 2/3 study, a single-arm Phase 2 study will be conducted first, and after favorable efficacy data are obtained, a Phase 3 study comparing against standard chemotherapy will then be conducted.

研究概览

地位

尚未招聘

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed written informed consent, voluntarily participating in this study.
  2. Age ≥ 18 years, male or female.
  3. Patients with histopathologically or cytologically confirmed esophageal squamous cell carcinoma who cannot be treated surgically and have failed 1L standard of care (SoC) .
  4. MTAP deficiency is confirmed by IHC or NGS .
  5. At least one measurable lesion as per RECIST v1.1 criteria.
  6. ECOG performance status of 0 or 1.
  7. Life expectancy > 3 months.
  8. Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory.
  9. Has a negative serum pregnancy test result at screening and is able to comply with contraceptive-barrier requirements.

Exclusion Criteria:

  1. Previous anti-tumor treatments did not meet the elution deadline requirements specified in the protocol; .
  2. Known or suspected that there is an allergy to GH56 active ingredients and/or GH56 capsule excipients;
  3. Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
  4. Tumor invasion of the central nervous system, large blood vessels, trachea, serosal cavity, and other areas may have a significant impact on the compliance, safety, and efficacy evaluation of this trial .
  5. Patients cannot take oral medication or has severe absorption disorders .
  6. Unresolved toxicity from prior anti-cancer therapy.
  7. Patients with uncontrolled clinical symptoms or disease such as other malignant tumors, cardiovascular and cerebrovascular diseases, nervous/mental diseases, respiratory diseases, digestive diseases, immune and infectious diseases.
  8. Active infection of HIV, HBV, syphilis or HCV .
  9. Conditions that the investigator considers inappropriate for participation in this clinical trial.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:GH56 Capsule Group

GH56 RP2D administered to patients with MTAP-Deleted ESCC

Planned dose administered on specified days per protocol

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:Approximately 2 years

The percentage of participants having complete response (CR) or partial response (PR) assessed based on RECIST V1.1

Approximately 2 years

次要结果测量

结果测量
措施说明
大体时间
Progression-Free Survival (PFS)
大体时间:Approximately 2 years

Progression-Free Survival assessed by investigators based RECIST v1.1

Approximately 2 years
Overall Survival (OS)
大体时间:Approximately 2 years

Overall Survival after first dose

Approximately 2 years
Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)
大体时间:Approximately 2 years

Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs

Approximately 2 years
Pharmacokinetic characteristics of GH56
大体时间:Approximately 2 years

Plasma Concentration of GH56

Approximately 2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:bo Zheng Song, Doctorate、Zhejiang Cancer Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月31日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2028年12月31日

研究注册日期

首次提交

2026年11月10日

首先提交符合 QC 标准的

2026年11月10日

首次发布 (实际的)

2026年11月16日

研究记录更新

最后更新发布 (实际的)

2026年11月16日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • GH56C204

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅